UPDATE: Morgan Keegan Lowers Price Target on Epocrates to $8.39

According to Morgan Keegan, Epocrates

price target is lowered to $16. Morgan Keegan said that EPOC has a unique footprint of 340,000 physicians that use its handheld drug reference software. “Our new December quarter estimate is $0.04 on $28.5 million versus the consensus of $0.07 on $32.3 million.” Epocrates closed yesterday at $8.39.